- Kane Biotech (KNE) wound care commercialization to be a key focus in 2022
- Kane is anticipating that its DispersinB® wound gel will be a game-changer in the industry
- It plans to launch its coactiv+™ wound gel by early 2023 and meet all the regulatory requiremnets to do so
- Kane estimates the U.S. market for wound care hydrogels to be approximately USD $200M
- Kane Biotech (KNE) is up 3.23 per cent, trading at C$0.16 at 12:49 pm EST
Kane Biotech (KNE) CEO, Marc Edwards views the company’s history of biofilm research and development as a strategic advantage.
“Biofilms in wound care have been an increasing topic of discussion amongst industry professionals for less than a decade but have now grown to be recognized as one of the biggest unresolved problems,” said Edwards
“This is a huge opportunity for Kane as our focus has exclusively been biofilms for the past 20 years and we are moving towards commercialization on not one but two important products,” added Edwards.
“We anticipate that our DispersinB® wound gel will be a game-changer in the industry and the funding we’ve received from the U.S. Army through the Medical Technology Enterprise Consortium (MTEC) as well as from Western Economic Diversification Canada is a testimony to that,” added Edwards.
“In the meantime, our plan for 2022 is to have met all the regulatory requirements to launch our coactiv+™ wound gel by early 2023, subject to FDA approval, as we believe it will have a significant impact on biofilm impaired wounds on a number of levels,” concluded Edwards.
A milestone for Kane is the commencement of human clinical trials on its DispersinB® wound gel in Q2 2022.
The results of preclinical safety and biocompatibility data are very encouraging, suggesting high efficacy and safety.
It is also looking to launch its coactiv+™ Wound Gel.
Use of the coactiv+™ technology in wound care products will complement the company’s disruptive DispersinB® wound care product development efforts whilst enabling the pursuit of the simpler 510(k) regulatory route and potentially quicker market access.
Kane estimates the U.S. market for wound care hydrogels to be approximately USD $200M.
The signing of a commercial partnership, similar to the one structured in animal health in 2020 but at a significantly higher valuation, is progressing.
The expertise, reach and extensive sales force of a large global wound care partner will be transformational for the company.
Kane Biotech (KNE) is up 3.23 per cent, trading at C$0.16 at 12:49 pm EST.